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A potent antimalarial benzoxaborole targets
a Plasmodium falciparum cleavage and
polyadenylation specificity factor homologue
Ebere Sonoiki1,2,*, Caroline L. Ng3,*, Marcus C.S. Lee3,w, Denghui Guo1, Yong-Kang Zhang4, Yasheen Zhou4,
M.R.K. Alley4, Vida Ahyong5, Laura M. Sanz6, Maria Jose Lafuente-Monasterio6, Chen Dong4,
Patrick G. Schupp3, Jiri Gut1, Jenny Legac1, Roland A. Cooper7, Francisco-Javier Gamo6, Joseph DeRisi5,
Yvonne R. Freund4, David A. Fidock3,8 & Philip J. Rosenthal1
Benzoxaboroles are effective against bacterial, fungal and protozoan pathogens. We report
potent activity of the benzoxaborole AN3661 against Plasmodium falciparum laboratory-
adapted strains (mean IC50 32 nM), Ugandan field isolates (mean ex vivo IC50 64 nM),
and murine P. berghei and P. falciparum infections (day 4 ED90 0.34 and 0.57mg kg
 1,
respectively). Multiple P. falciparum lines selected in vitro for resistance to AN3661
harboured point mutations in pfcpsf3, which encodes a homologue of mammalian cleavage
and polyadenylation specificity factor subunit 3 (CPSF-73 or CPSF3). CRISPR-Cas9-mediated
introduction of pfcpsf3 mutations into parental lines recapitulated AN3661 resistance.
PfCPSF3 homology models placed these mutations in the active site, where AN3661 is
predicted to bind. Transcripts for three trophozoite-expressed genes were lost in AN3661-
treated trophozoites, which was not observed in parasites selected or engineered for AN3661
resistance. Our results identify the pre-mRNA processing factor PfCPSF3 as a promising
antimalarial drug target.
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D
espite efforts to curb transmission, malaria remains
an important global infectious disease, accounting for
an estimated 212 million cases and 429,000 deaths world-
wide in 2015 (ref. 1). Challenges to the control and elimination of
malaria include widespread drug resistance in Plasmodium
falciparum, the most virulent human malaria parasite. As
older regimens are limited by resistance, artemisinin-based
combination therapies have been adopted as the standard of
care for the treatment of uncomplicated falciparum malaria1.
However, resistance to artemisinins has emerged in Southeast
Asia2,3, and resistance has been seen to most artemisinin-based
combination therapy partner drugs4. The development of new
antimalarial agents with novel modes of action is urgently needed.
Benzoxaboroles are boron-containing compounds that have
shown potent activity against a wide range of infectious
pathogens, including bacteria5,6, fungi7 and protozoans8–12. The
highly electrophilic nature of the boron component of these
compounds leads to interaction with a variety of protein targets
via reversible covalent bonds13,14, with identified targets
including leucyl-tRNA synthetase (LeuRS)6,7, phosphodiesterase
4 (PDE4)15,16 and b-lactamase17. Tavaborole, the first
benzoxaborole to receive FDA approval, is an inhibitor of
fungal LeuRS that is used to treat onychomycosis18. Crisaborole,
a PDE4 inhibitor, has completed phase 3 clinical trials for atopic
dermatitis.
This manuscript reports the antimalarial profile and mechan-
ism of action of another benzoxaborole, AN3661, which was
identified from a screen of a benzoxaborole library against
cultured P. falciparum asexual blood stage parasites19,20. AN3661
demonstrated potent antimalarial activity, and genetic and
biochemical studies identified its target as a homologue of
mammalian cleavage and polyadenylation specificity factor
(CPSF) subunit 3.
Results
In vitro characterization of AN3661 activity. An in vitro screen
of a benzoxaborole library19,20 against the multidrug-resistant
P. falciparum W2 strain identified the 7-[(20-carboxylic acid)
ethyl] benzoxaborole AN3661 (Fig. 1a). AN3661 was active at
nanomolar concentrations against P. falciparum laboratory
strains known to be sensitive (3D7) or resistant (W2, Dd2, K1,
HB3, FCR3 and TM90C2B) to standard antimalarial drugs, and it
was similarly active in ex vivo studies of fresh Ugandan field
isolates (Fig. 1b and Supplementary Table 1). There was no
difference in AN3661 potency between drug-sensitive or
-resistant parasite strains (Supplementary Table 2). AN3661
showed minimal cytotoxicity against mammalian cell lines, with
the CC50 60.5 mM against Jurkat cells, and all other CC50 values
greater than the highest concentrations tested (25 mM or above;
Supplementary Table 3).
When cultured with the P. falciparum 3D7 strain, AN3661
reduced the number of viable parasites in a time- and dose-
dependent manner (Supplementary Fig. 1a). Parasites exposed to
10 IC50 concentrations of AN3661 reduced parasitemia with a
rate of killing similar to that of pyrimethamine (Supplementary
Fig. 1b). However, exposure to 30 IC50 increased the rate of
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Figure 1 | Activity of AN3661 against P. falciparum laboratory-adapted
strains and field isolates. (a) Chemical structure of AN3661.
(b) Susceptibility of laboratory strains and field isolates to AN3661. Bar
graphs represent mean±s.e.m. IC50 values. Each point in the dot plot
represents one field isolate; the horizontal bar indicates the mean value.
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Figure 2 | AN3661 efficacy in murine malaria models (a) AN3661 efficacy
in P. berghei-infected mice. Mice (4–5 animals for each concentration
tested) were treated orally with the indicated dosages of AN3661,
chloroquine or vehicle daily for 4 days. Infections were monitored daily by
Giemsa-stained blood smears, and mice were euthanized when
parasitemias exceeded 50%. (b) AN3661 efficacy in P. falciparum-infected
mice. Mice with B40% circulating human erythrocytes were intravenously
infected with 2 107 P. falciparum-infected erythrocytes on day 0, and
AN3661 was then administered by oral gavage at the indicated dosages for
4 consecutive days (arrows). Parasitemia was measured by flow cytometry
daily until day 7. Mean parasitemias for three mice in each group are
shown. Error bars represent s.e.m.
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killing, with a profile similar to that of chloroquine. From these
results, the minimum concentration of AN3661 required to
obtain the fastest kill rate was 1.38 mM.
AN3661 activity in murine malaria models. When administered
orally for 4 days to P. berghei-infected mice, beginning on the day
of infection, AN3661 rapidly controlled parasitemias, with a 90%
effective dose (ED90) 4 days after initiation of treatment of
0.34mg kg 1. Daily dosages of 50mg kg 1 and 100mg kg 1
extended survival compared to untreated controls, and mice
treated with 200mg kg 1 per day demonstrated long-term cures
(Fig. 2a). We also investigated compound efficacy against
P. falciparum in a murine model using NODscidIL-2Rgnull
mice engrafted with human erythrocytes and infected with
P. falciparum21. When AN3661 was administered orally for
4 days, beginning on the third day of infection, the ED90 4 days
after initiation of treatment was 0.57mg kg 1 (Fig. 2b).
Stage specificity and morphology of treated parasites.
Synchronized W2 strain parasites were exposed to AN3661 for
8-h intervals across the asexual blood stage cycle, and subsequent
ring-stage parasitemias were compared to those of untreated
controls. Inhibitory effects of AN3661 were greatest in early to
middle trophozoite-stage parasites, as found with the reference
drug chloroquine (Fig. 3a). Parasites treated with 370 nM
AN3661, beginning at the early ring stage, appeared morpho-
logically normal through late rings, but could not progress
beyond the trophozoite stage, with the appearance of shrunken,
pyknotic parasites (Fig. 3b).
In vitro selection of parasites resistant to AN3661. We quan-
tified the ease of in vitro selection of resistance to AN3661 by
subjecting 106–108 Dd2 strain parasites to 60 nM (2 IC90)
AN3661. Regrowth was seen in two of three cultures with initial
inocula of 106 parasites at days 45 and 56, one of three cultures
with initial inocula of 107 parasites at day 23, and three of
three cultures with initial inocula of 108 parasites, all on day 19
(Supplementary Table 4). These rates of resistance selection were
similar to those observed for atovaquone.
To determine the target of AN3661, we employed two separate
methods of generating resistant mutants. In the first, we
pressured W2 and Dd2 strains of P. falciparum with increasing
concentrations of AN3661 (37 nM–5 mM). In the second, a single
concentration of AN3661 (170 nM) was applied to Dd2 parasites
(Fig. 4a). Using the first method, for the W2 strain, 5 steps of
continuous selection over 11 months led to a 200-fold decrease
in sensitivity to AN3661 (Fig. 4b). After selection, W2 parasite
lines with medium to high-level resistance (W2-R3, W2-R4 and
W2-R5; with mean IC50 0.7, 6.2 and 15.3 mM, respectively,
compared to 31 nM for the W2 parental line) were cultured
without drug pressure to test the stability of the resistance
phenotype. In each case, revertant parasites were obtained that
showed decreased resistance to AN3661 after culture without the
compound. For W2-R3 parasites, the revertant (W2-R3rev) had
roughly the sensitivity of the parental W2 strain, but W2-R4 and
W2-R5 revertants retained micromolar IC50 values indicating
only partial loss of resistance. Results with Dd2 were similar to
those with W2, with AN3661-resistant parasites obtained in
4 separate selections (mean IC50 0.2–0.9 mM, compared to 22 nM
for the Dd2 parental line, Fig. 4c). Selection for resistance to
AN3661 was accompanied by only modest changes in sensitivity
to the standard antimalarial chloroquine (Supplementary
Table 5).
Whole-genome sequence analysis of AN3661-resistant parasites.
Whole-genome sequence analysis and confirmatory dideoxy
sequencing of W2 and Dd2 parental and AN3661-resistant clonal
lines revealed both copy number variations (CNVs) and non-
synonymous single-nucleotide polymorphisms (SNPs) in selected
lines, compared to their parental lines (Supplementary Table 6).
Importantly, every AN3661-resistant parasite line harboured
mutations in pfcpsf3 (PF3D7_1438500). This gene encodes a
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Figure 3 | Stage specificity of AN3661. (a) W2 parasites were treated with 370 nM AN3661 or 1.3mM chloroquine (CQ) for 8-h time intervals across the
asexual erythrocytic cycle. Compounds were removed at the end of each 8 h interval, cultures were continued and parasitemias were determined after 48 h.
Bar graphs indicate the mean±s.e.m. parasitemia of treated parasites as a percentage of untreated controls. (b) W2 parasites treated with 370 nM
AN3661 beginning in the early ring stage and untreated controls were collected at the indicated time points, stained with Giemsa, and photographed.
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homologue of subunit 3 of the CPSF complex, which has been well
characterized in various eukaryotes22. In humans, this subunit has
endonuclease activity and is referred to as CPSF-73, based on its
molecular weight of 73 kDa. The predicted molecular weight of the
P. falciparum homologue PfCPSF3 is 101 kDa. Dd2 parasites
resistant to AN3661 had single PfCPSF3 mutations (T406I, Y408S,
T409A or D470N; Fig. 4c). W2 parasites resistant to AN3661
demonstrated a more complex resistance trait: low-level resistant
parasites had wild-type PfCPSF3, but high-level resistance was
conferred by a single mutation, D470N, or a double mutation,
H36Y/D470N.
We also applied whole-genome sequence analysis to
revertant parasite lines that had been cultured without AN3661
after resistance selection. W2-R3rev, which showed wild-type
sensitivity to AN3661 (mean IC50 23.4 nM), had lost the PfCPSF3
D470N mutation, but W2-R4rev, which remained resistant
(IC50 3.0 mM), retained the double PfCPSF3 H36Y/D470N
mutation. Low-level resistance to AN3661 observed in W2-R1
and W2-R2 was accompanied by amplification in the region of
chromosome 5 (position 946,695–971,095) that encompasses
pfmdr1 (PF3D7_0523000; Fig. 4b). This gene encodes an ABC
transporter for which SNPs and CNV have been linked to altered
sensitivity to a number of antimalarials23.
pfcpsf3 gene editing recapitulated AN3661 resistance. To
test the hypothesis that mutations in PfCPSF3 constitute the
primary determinant of P. falciparum resistance to AN3661, we
engineered Dd2 parasites to harbour either the T406I or Y408S
mutations observed in our resistant lines. These experiments
utilized a CRISPR-Cas9-based method of gene editing (Fig. 5a
and Supplementary Table 7). Transfections yielded three parasite
lines carrying the T406I mutation and two carrying the Y408S
mutation. While most transfections included selection with
170 nM AN3661, importantly transfectant C4 (PfCPSF3 Y408S)
did not, and rather was obtained using only WR99210 and
blasticidin selection of the editing plasmids. All transfectants
demonstrated 100% editing efficiency at the appropriate sites in
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the genome, including silent mutations at the single-guide RNA
(sgRNA)-directed Cas9 binding sites (Fig. 5b). In the engineered
parasites, the PfCPSF3 T406I and Y408S mutations conferred a
12–50-fold decrease in AN3661 sensitivity, similar to changes in
sensitivity in parasites that acquired these mutations after in vitro
resistance selection (Fig. 5c). Selected and transfected parasites
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with the Y408S mutation were consistently less sensitive to
AN3661 compared to parasites with the T406I mutation. These
results confirm a primary role for pfcpsf3 mutations in conferring
resistance to AN3661.
Resistance mutations cluster around the enzyme active site.
Amino acid sequence alignment showed that PfCPSF3 is a close
homologue of human CPSF-73 (Fig. 6a), with 61% similarity and
39% identity (calculations did not include gaps in the alignment
due to plasmodial insertions). A crystal structure of human
CPSF-73 (PDB code: 2I7T) revealed that the enzyme belongs to
the zinc-dependent metallo-b-lactamase (MBL) family, with MBL
and b-CASP domains, and an active site at the interface of these
domains containing two zinc ions24. Since this crystal structure
appears to be in an inactive conformation, with the b-CASP
domain occluding the active site, we generated a new model based
on a crystal structure of the messenger RNA (mRNA) processing
ribonuclease TTHA0252 from Thermus thermophiles HB8 (PDB
code: 3IEM), an enzyme with 47% similarity and 27% identity
with PfCPSF3. This structure was in an active conformation
complexed with an RNA analogue in the active site. In the T.
thermophiles-based PfCPSF3 model the b-CASP domain does not
occlude the bi-metal active site, which is accessible to substrates
and inhibitors (Fig. 6b). In both models, the identified PfCPSF3
resistance mutations T406I, Y408S, T409A and D470N clustered
around the active site (Fig. 6b). This finding suggests functional
relevance of the resistance mutations and supports the genetic
evidence implicating PfCPSF3 as the antimalarial target of
AN3661.
Molecular docking suggests oxaborole binding to PfCPSF3.
Considering the conformational complexity of the PfCPSF3
active site and limitations of forcefield parameters involving
the boron atom, we docked AN3661 by matching important
pharmacophore sites in the PfCPSF3 homology model based on
T. thermophiles. The negatively charged tetrahedral oxaborole
group from AN3661 was placed at the phosphate position at
the cleavage site, interacting with the two catalytic zinc ions.
Analogous interaction with metals has been seen in crystal
structures of oxaboroles binding to PDE4 (ref. 16) and MBL
NDM-1 (YR Freund, personal communication), with the
oxaborole group acting as a transition state mimic and a
phosphate mimic, respectively. The energy-minimized model of
AN3661 at the active site of PfCPSF3 revealed the terminal
carboxylate of AN3661 occupying an adjacent phosphate-binding
site opposite R290 and Y252, forming a salt bridge and a
hydrogen bond, respectively (Fig. 6b). Of the residues selected in
AN3661-resistant parasites, Y408 and T409 were located at the
entrance of the binding pocket in the b-CASP domain, in close
proximity to the docked inhibitor, and D470 was positioned
opposite Y408 in the RNA-metabolizing MBL domain (Fig. 6b).
T406 was adjacent to R290, which directly interacts with the
carboxylate from AN3661. It is interesting to note that in the
Toxoplasma gondii CPSF-73 homologue, a Y328C (corresponding
to Y252 in PfCPSF3) resistance mutation was selected under
AN3661 pressure25, further supporting the hypothesis that this
residue is important in AN3361 binding.
AN3661 inhibited the stability of P. falciparum transcripts.
The mammalian CPSF complex is required for the processing
of newly synthesized transcripts (pre-mRNAs) to mature
mRNA24,26,27. The cleavage of the 30 end of pre-mRNA and
subsequent addition of a poly(A) tail is necessary for mRNA
stability and for export of mature mRNA from the nucleus to the
cytosol, where it acts as a template for translation26. The observed
similarity between PfCPSF3 and human CPSF-73 led us to
predict that inhibition of PfCPSF3 would impact the stability of
parasite mRNA transcripts. As AN3661-treated parasites failed to
progress through the trophozoite stage (Fig. 3a), we suspected
that a defect in mRNA stability would be most apparent in
trophozoites. We thus examined transcripts for three trophozoite-
expressed genes, falcipain-2 (FP2), 1-cys peroxiredoxin and
purine nucleoside phosphorylase (PNP)28–30 in parasites
cultured in the presence or absence of AN3661. Following a
4-h incubation with either AN3661 or the transcription initiation
inhibitor actinomycin D, FP2, 1-cys peroxiredoxin and PNP
transcripts were markedly reduced or undetectable in parental
W2 and Dd2 parasites (Fig. 7a,e; Supplementary Figs 2 and 3). In
contrast, parasites harbouring the PfCPSF3 mutations D470N,
H36Y/D470N, T406I or Y408S selected with AN3661 or
introduced with the CRISPR-Cas9 system demonstrated stable
transcripts despite exposure to AN3661 (Fig. 7c,d,f–i). In all
parasites examined, transcripts were unstable in the presence of
actinomycin D, yet were unaffected by 4-h exposures to
artemisinin or chloroquine, antimalarials that have unrelated
modes of action (Fig. 7). Taken together, our data provide
compelling evidence that AN3661 selectively inhibits PfCPSF3,
leading to altered parasite mRNA processing and stability.
Discussion
Screening of a benzoxaborole library against cultured
P. falciparum identified AN3661 as a potent antimalarial lead
compound. Subsequent studies showed AN3661 to be active at
low nanomolar concentrations against multiple P. falciparum
strains that vary in their susceptibility to standard antimalarials
and to be highly effective when administered orally to treat
P. berghei and P. falciparum infections in mice. Multiple
independently selected parasites with resistance to AN3661
contained mutations in the P. falciparum homologue of the
endonuclease component of the CPSF complex that has been
shown in other organisms to be responsible for pre-mRNA
cleavage and polyadenylation24. Introduction of two of these
PfCPSF3 mutations into wild-type parasites recapitulated
resistance to AN3661, and modelling suggested that the
mutations were in the PfCPSF3 active site at amino acids
interacting with AN3661. Biochemical studies showed that
treatment with AN3661 led to alterations in the stability of
messages encoding three trophozoite proteins in wild-type,
but not AN3661-resistant parasites. Collectively, these results
support the conclusion that the primary target of AN3661 in
P. falciparum is PfCPSF3.
CPSF is a multi-protein complex present in eukaryotic cells
that is essential for processing of pre-mRNA to mRNA via
cleavage and polyadenylation at the 30-end of the pre-mRNA. In
mammals, the coordinated activity of the CPSF complex and
other proteins is initiated by interaction of CPSF-100 with an
AAUAAA sequence located 10–30 bases upstream of the cleavage
site22,24,26,31,32. Upon interaction with the AAUAAA sequence,
the pre-mRNA undergoes site-specific endonucleolytic cleavage
by CPSF-73 to generate the mRNA end, which then serves as a
primer for synthesis of the poly(A) tail26. The endonuclease
CPSF-73 is a member of the zinc-dependent MBL family, and
contains 5 canonical MBL signature sequence motifs of histidine
and aspartate residues, as well as a b-CASP domain24,26,33.
The active site of CPSF-73 contains two zinc ions and is located at
the interface of the MBL and b-CASP domains. PfCPSF3 is a
homologue of mammalian CPSF-73 with conservation of the
5 MBL and b-CASP motifs.
Homology modelling of the structure of PfCPSF3 offered
further support for its role as the target of AN3661. The
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Figure 6 | AN3661 resistance mutations reside in the MBL and b-CASP domains of PfCSPF3. (a) Conserved domains predicted by NCBI for PfCPSF3 and
its homologues in humans (Hs, gi:18044212), Toxoplasma gondii (Tg, KFG54681.1) and T. thermophilus (Tt, TTHA0252). R, RNA-metabolizing MBL domain.
Amino acid numbers are shown for each protein. Asterisks denote amino acids predicted to bind the two zinc atoms in the MBL domain. Amino acids in red
were mutated after drug selection. (b) Model of AN3661 (cyan) at the active site of PfCPSF3 (MBL domain, mauve; b-CASP domain, green,
RNA-metabolizing MBL domain, orange), built based on the crystal structure of T. thermophilus TTHA0252 (PDB code: 3IEM). Residues D470, Y408, T409
and T406, which were mutated after selection by AN3661, are shown as blue stick models. The negatively charged benzoxaborole group interacts
extensively with the two catalytic zinc ions (grey), and the carboxylate side chain interacts with R290 and Y252, forming a salt bridge and hydrogen bond,
respectively.
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mutations seen in P. falciparum after selection for decreased
sensitivity to AN3661 were in residues predicted to be in the
enzyme’s active site and in proximity to AN3661. Remarkably, in
parallel studies with T. gondii, a related apicomplexan parasite,
selection of resistance to AN3661 was accompanied by mutations
in the predicted active site of the T. gondii homologue of
CPSF3 (ref. 25). Our docking model of AN3661 at the PfCPSF3
binding site is consistent with the structure-activity relationships
established for this series of compounds as antimalarial agents.
First, the oxaborole group is essential for activity, as replacement
of a carbon atom for the boron resulted in an inactive
compound20. Second, the carboxylic acid group is important for
activity, although it can be replaced by other acidic groups such as
a tetrazole19. The negatively charged tetrahedral oxaborole group
serves as a unique ion chelator engaging the two zinc ions at the
active site. The fact that AN3661 could be modelled into the
bi-metal active site of PfCPSF3 is consistent with findings for
other benzoxaboroles, which have been demonstrated to bind to
bi-metal centres. In the active site of PDE4, which contains a zinc
and a magnesium ion, the boron atom of AN2898 binds to the
activated water molecule in the bi-metal centre and mimics
the transition state of the substrate cAMP16. In the co-crystal
structure of NDM-1 MBL and a benzoxaborole b-lactamase
inhibitor, AN4483, the boron atom is coordinated to the bi-zinc
centre, similar to the predicted binding conformation for AN3661
in PfCPSF3 (YR Freund, personal communication). These
examples demonstrate the potential of the oxaborole group in
benzoxaboroles such as AN3661 to act as a metal chelator capable
of binding to a variety of enzymes containing bi-metal centres.
In our parasite drug pressuring studies, low-level resistance to
AN3661 was associated with increased copy number for pfmdr1,
which encodes a presumptive ABC transporter23. Increased
pfmdr1 copy number has previously been associated with
decreased sensitivity to the arylaminoalcohols mefloquine,
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Figure 7 | mRNA stability in the presence of AN3661. Northern blots shown are of parasite lines labelled as defined in Figs 3 and 4 (a–i) that were treated
for 4 h with DMSO (untreated), actinomycin D, AN3661, artemisinin or chloroquine. RNA was then processed and the transcripts for purine nucleoside
phosphorylase (PNP), 1-cys peroxiredoxin (1-CysPxn) and FP2 were detected and imaged as described in ‘Methods’ section. Levels of 28S rRNA were
examined as a loading control. The figure shows results from a single experiment. Two additional experiments yielded the same results.
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lumefantrine and halofantrine, and increased sensitivity to the
4-aminoquinolines chloroquine and amodiaquine4. Alterations in
pfmdr1 copy number may impact AN3661 accumulation at its
intracellular site of action. However, high-level resistance to
AN3661 was not associated with pfmdr1 copy number, suggesting
that alterations in PfCPSF3 are the dominant determinant for
high-grade resistance.
Antimalarial drug discovery presents significant challenges.
New antimalarials should meet multiple criteria, including
excellent potency, ideally against multiple plasmodial species;
oral bioavailability, ideally with cure after a single dose; safety in
children and pregnant women; and low cost of production34.
AN3661 shows progress in this direction as it displays
outstanding potency against multiple strains of P. falciparum
in vitro and is highly effective when administered orally in mouse
models of P. falciparum and P. berghei infection. However,
resistance was selected fairly readily in vitro, raising concern
about clinically relevant selection of resistance. This concern may
be obviated by incorporating PfCPSF3 inhibitors into
combination regimens. The discovery of PfCPSF3 as the target
for AN3361 enables us to rationally design inhibitors with
improved drug-like properties and additional interactions that
should reduce the propensity for resistance while maintaining
selectivity.
Methods
Activity of compounds against cultured P. falciparum. P. falciparum strains
(3D7, W2, Dd2, K1, HB3, FCR3 and TM90C2B; obtained from the Malaria
Research and Reference Reagent Resource Center) were cultured by standard
methods at 2–3% haematocrit in Roswell Park Memorial Institute (RPMI)-1640
medium (Invitrogen) supplemented with 0.5% Albumax II (GIBCO), 2mM
L-glutamine, 100mM hypoxanthine, 5 mgml 1 gentamicin, 28mM NaHCO3 and
25mM HEPES at 37 C in an atmosphere of 5% O2, 5% CO2 and 90% N2, except
that for parasite reduction ratio studies (Supplementary Fig. 1) parasites were
cultured at 2% haematocrit in RPMI-1640 medium supplemented with 0.5%
Albumax II, 2% D-sucrose, 0.3% glutamine and 150mM hypoxanthine. In vitro
dose-response assays were conducted in one of three ways. In the first, parasites
were synchronized by treatment with 5% D-sorbitol and cultured in duplicate
96-well culture plates (200 ml per well) in the presence of serially diluted AN3661 or
chloroquine (Sigma-Aldrich). Compound concentrations ranged from 0.056 to
1,000 nM. Control wells contained r0.2% dimethylsulphoxide (DMSO). After
48 h, the cultures were fixed with 2% formaldehyde for 24 h at 37 C or 48 h
at room temperature. Fixed cells were then stained with 4 nM YOYO-1 dye
(Molecular Probes), and counts of treated and control cultures were determined
using a fluorescence-activated cell sorter. In the second method, parasites that were
mostly rings were seeded in 96-well culture plates at 1% haematocrit and 0.2%
parasitemia. Parasites were subjected to a range of drug concentrations, with final
DMSO concentrations r0.2%, for 72 h. Live parasites were stained with SYBR
Green I (Invitrogen) and 100 nM MitoTracker Deep Red (Invitrogen), quantified
by flow cytometry analysis on a BD Accuri C6 and analysed using FlowJo software.
In the third method, parasites at 2% haematocrit and 0.5% parasitemia were
exposed to a range of drugs for 48 h, and parasitemia was then quantified by
[3H]-hypoxanthine incorporation. IC50 values were calculated by nonlinear
regression using GraphPad Prism 6.0 software.
Ex vivo dose response against P. falciparum field isolates. The activity of
AN3661 was tested against fresh P. falciparum isolates using an enzyme-linked
immunosorbent assay directed against the histidine-rich protein-2, as previously
described35,36. These isolates were collected in 2012 from children with
P. falciparum malaria living in Tororo, Uganda, before receipt of drug treatment.
The relevant clinical trials and analyses of cultured parasites were approved by the
Uganda National Council of Science and Technology, the Makerere University
Research and Ethics Committee, and the University of California, San Francisco
Committee on Human Research.
Cellular cytotoxicity assay. Studied mammalian cells (all received from,
authenticated by, and noted to be Mycoplasma-free by the American Type Culture
Collection, see Supplementary Table 3) were seeded into 96-well plates at 2 104
cells per well in 100 ml growth medium (RPMI-1640 medium with 10% foetal
bovine serum and 2mM L-glutamine) with 10-fold serial dilutions
(0.1 nM–100 mM) of AN3661; control wells had the same concentration of DMSO
(0.25%). Plates were incubated at 37 C in 5% CO2 for 72 h. MTS (20ml;
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) was then added for 4 h, and absorbance was determined at 490 and
690 nm. Inhibition of cell viability was calculated based on the formula:
% inhibition of cell viability¼ 100—(DODtreated/DODuntreated) 100
(DOD¼OD490OD690).
In vitro parasite reduction ratio. This assay used limiting dilution to quantify the
number of parasites that remained viable after various durations of treatment.
P. falciparum 3D7 parasites (at 2% haematocrit and 0.5% parasitemia) were
incubated with AN3661 for 24, 48, 72, 96 or 120 h. After appropriate time points,
the compound was removed by washing, and parasites were serially diluted in 96-
well plates and allowed to continue growing after drug wash-out. The number of
viable parasites after various incubation times with compounds was determined
after 21 and 28 days by measuring [3H]-hypoxanthine incorporation in threefold
serial dilutions of cultures, as previously reported37. Human biological samples
were sourced ethically, and their research use was in accord with the terms of
informed consents.
Activity of AN3661 in murine models of malaria. Protocols for studies of
murine P. berghei infection were approved by the University of California, San
Francisco Institutional Animal Care and Use Committee. Female Swiss Webster
mice (6–8 weeks of age; 18–20 gm) were infected intraperitoneally with 6 106
P. berghei-infected erythrocytes (passaged from a donor mouse) and then treated,
beginning 1 h after inoculation, with AN3661 (in 55% polyethylene glycol 300, 25%
propylene glycol, 20% water) or chloroquine (in water) by oral gavage once daily
for 4 days. Treatment group assignments were allocated randomly. Investigators
were not blinded to treatment groups. Negative controls were treated with vehicle
only. Infections were monitored by daily microscopic evaluation of Giemsa-stained
blood smears. ED90 values, based on comparisons of parasitemias between treated
and control animals on the fourth day after the initiation of treatment, were
calculated using GraphPad Prism 6.0 software. Mice were euthanized when
parasitemias exceeded 50%.
Studies of murine P. falciparum infection were ethically reviewed and carried
out in accordance with European Directive 2010/63/EU and the GSK Policy on the
Care, Welfare and Treatment of Animals. In vivo efficacy against P. falciparum was
conducted as previously described21. Age-matched female immunodeficient
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (8–10 weeks of age; 22–24 gm) supplied by
Charles River, L’Arbresle, France, under license of The Jackson Laboratory, Bar
Harbor, ME, USA were engrafted with human erythrocytes (Red Cross Transfusion
Blood Bank in Madrid, Spain) by daily intraperitoneal injection with 1ml of a 50%
haematocrit erythrocyte suspension (RPMI-1640 (Invitrogen), 25mM HEPES
(Sigma), 25% decomplemented ABþ human serum (Sigma) and 3.1mM
hypoxanthine (Sigma)). The sample size per experimental group was 3, calculated
as the minimum required to detect 50% reduction in parasitemia compared to a
vehicle-treated control group, assuming a value for a (confidence level) of 0.05 and
a value for b (power) of 0.9. Mice with B40% circulating human erythrocytes were
intravenously infected with 2 107 P. falciparum Pf3D70087/N9-infected
erythrocytes (day 0). AN3661 was then administered by oral gavage for 4
consecutive days, beginning on day 3 after infection. AN3661 was prepared in 1%
carboxymethylcellulose 0.1% Tween 80 in water before administration. Treatment
group assignments were allocated randomly. Investigators were not blinded to
treatment groups. Parasitemia was measured by flow cytometry in samples of
peripheral blood stained with the fluorescent nucleic acid dye SYTO-16 (Molecular
Probes; S-7578, 5 mM) and anti-murine erythrocyte TER119 monoclonal antibody
(Becton Dickinson 553673; 10 mgml 1) in serial 2 ml blood samples taken every
24 h until assay completion. The ED90 was estimated by fitting a four parameter
logistic equation using GraphPad Prism 6.0.
Stage specificity assay. The stage-specific activity of AN3661 and chloroquine
was analysed as previously described10,38. Highly synchronous W2 strain
P. falciparum (synchronized by treatment with 5% D-sorbitol) were cultured in
triplicate wells in 96-well culture plates with 370 nM AN3661 or 1.3 mM
chloroquine for 8 h intervals, beginning at the ring stage. Control cultures
contained equivalent concentrations of DMSO (o0.2%). At the end of each
interval, the cultures were washed three times and resuspended in culture media
without drug. After 48 h, when control parasites were at the ring stage, the cultures
were fixed with 2% formaldehyde and counted using flow cytometry as detailed
above, and parasitemias were compared with those of untreated control parasites.
Selection of parasites with decreased sensitivity to AN3661. For step-wise
selection, triplicate 10ml cultures containing 6 107 asynchronous W2 strain or a
clonal population of the Dd2 strain were incubated with step-wise increasing
concentrations of AN3661. W2 parasites were subjected to 37 nM AN3661 for
43 days, 74 nM for 43 days, 300 nM for 90 days, 1 mM for 73 days and finally 5 mM
for 73 days. Dd2 parasites were subjected to 37 nM AN3661 for 31 days, then
200 nM for 73 days. For single-step resistance selection with Dd2, 2 109 parasites
in duplicate or 2 107 parasites were incubated with 170 nM AN3661. For the first
six days, parasitemia was monitored by microscopy and media containing drug was
changed daily. Then, media was changed every 2 days, and fresh erythrocytes were
replaced once a week. For all selections, parasitemia was monitored by microscopy,
and recrudescent parasites were cloned by limiting dilution.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14574 ARTICLE
NATURE COMMUNICATIONS | 8:14574 | DOI: 10.1038/ncomms14574 |www.nature.com/naturecommunications 9
Whole-genome sequencing. To prepare genomic DNA, synchronized
P. falciparum-infected erythrocytes (100ml, 2% haematocrit and 10% parasitemia)
were treated with 0.15% saponin for 5min on ice to lyse erythrocytes, followed by 3
washes in PBS. Parasite pellets were lysed in 150mM NaCl, 10mM EDTA, 50mM
Tris-HCl pH 7.5, 0.1% sarkosyl (Sigma-Aldrich) and 200mgml 1 proteinase K
(Qiagen) overnight at 37 C. The samples were then subjected to extraction
with phenol/chloroform/isoamyl alcohol (25:24:1) pH 7.9 (Ambion), treatment
with 0.05mgml 1 RNAse A (1 h at 37 C), two additional phenol/chloroform
extractions, one chloroform extraction and then ethanol precipitation. All phenol/
chloroform extractions were done using light phase lock tubes (5 Prime). Genomic
DNA libraries were prepared from 100 ng DNA using the Nextera DNA Sample
Prep Kit (Illumina) according to the manufacturer’s instructions, with the
exception that the number of cycles was 6 and the bridge amplification step was at
65 C for 6min39. Each library was barcoded with unique sets of two indices from
the Nextera Index Kit (Illumina) to allow multiple samples to be run on one flow
cell. Next, fragments of 360–560 bp were extracted and collected using Lab Chip
XT (Caliper Life Sciences) according to the manufacturer’s instructions. The
fragments were amplified by limited-cycle PCR using Kapa HiFi DNA polymerase
(Kapa Biosystems) with dNTPs with an 80% AT coding bias (6 cycles of 95 C for
10 s, 58 C for 30 s, 65 C for 6min). Primers used for both PCR steps are detailed
in Supplementary Table 8. Library concentrations were determined with a DNA
Bioanalyzer (Agilent), and libraries were pooled at concentrations of 2 nM per
library. Library preparations were then completed39 and sequenced at the UCSF
Center for Advanced Technology, followed by sequencing on a HiSeq 2000 system
(Illumina). Sequence data for each library were aligned to the 3D7 reference
genome using Bowtie40, discarding reads with41 nucleotide mismatch or multiple
alignments across the genome. For the identification of SNPs, reads were matched
to those from the parental strain, and the top 200 SNPs per chromosome, ranked
according to frequency of conflicting nucleotides per position in the genome, were
chosen and filtered based on standard parameters39. SNPs were characterized
as legitimate if the number of reads covering the position was 410 and the
frequency of the SNP was at least 80%. Searches for novel SNPs included only
non-synonymous SNPs in exons, excluding hypervariable genes (var, rifin and
stevor). CNV was analysed using the UCSC Genome Browser41.
Dideoxy sequencing. Genomic DNA was extracted using the QIAamp DNA mini
kit (Qiagen) according to the manufacturer’s instructions. The pfcpsf3 gene (listed
as PF3D7_1438500 on PlasmoDB) was amplified in 3 fragments using the Phusion
Hot Start II High-Fidelity DNA Polymerase kit (Thermo Scientific) with 80% AT
dNTPs and primers (Supplementary Table 8; 95 C for 3min, 30 cycles of 95 C for
10 s, 52 C for 30 s, 65 C for 1min and a final extension at 68 C for 10min). The
amplified fragments were cleaned using ExoSAP-IT (Affymetrix), mixed with
sequencing primers, and sequenced at the UCSF Genome Core Facility.
Determination of pfmdr1 copy number by quantitative PCR. Multiplex PCR was
performed in MicroAmp 96-well plates (Applied Biosystems) in 25 ml reactions
containing TaqMan mastermix buffer (8% glycerol, 0.625 U DNA polymerase,
5.5mM MgCl2, 300mM dNTP, 600 nM), reaction reference dye ROX
(5-carboxy-X-rhodamine), pH 8.3, 300 nM of each forward and reverse primer,
100 nM of each probe and 2.5 ml DNA template. The amplification protocol was
95 C for 10min, followed by 50 cycles of 95 C for 15 s and 58 C for 1min using
an Applied Biosystems 7500 Real Time PCR machine. b-tubulin was used as the
internal reference. Fluorescence data were analysed by a comparative Ct method
comparing changes in fluorescence signal of the target (pfmdr1) relative to the
internal reference (b-tubulin)42. All signals were normalized to the passive
reference signal (ROX). The detection threshold was set above the mean baseline
value for fluorescence of the first 15 cycles. Primer sequences are detailed in
Supplementary Table 8.
CRISPR-Cas9-mediated editing of pfcpsf3 mutations. Choice of sgRNA,
plasmid construction and parasite transfections were performed as described in
ref. 43. Briefly, the sgRNA 50-GGGAAGCCATAATAACACATGGG-30 (PAM site
underlined) was identified with the help of the Broad Institute’s sgRNA Designer
(https://www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design). The
chosen sgRNA was close to the mutations of interest (78 and 82 bp away),
had a high sgRNA score (0.68), and was unique in the genome (https://
chopchop.rc.fas.harvard.edu). The sgRNA construct with overhanging BbsI sites
was inserted into a pDC2-cam-Cas9-U6-hdhfr plasmid43 that encodes
Streptococcus pyogenes Cas9 expressed under the calmodulin promoter and a
human dhfr selectable marker (that mediates resistance to WR99210); the sgRNA
was expressed from a U6 promoter. A B1.4 kb fragment of pfcpsf3 was amplified
from Dd2 (pfcpsf3 wt), Dd2-Ra (pfcpsf3 C1217T) and Dd2-Rb (pfcpsf3 A1223C)
parasites using primers p5150 and p5151, detailed in Supplementary Table 8. Using
the Q5 Site-Directed Mutagenesis Kit (NEB), three or nine nucleotide substitutions
were introduced into the donor sequences at sgRNA-binding sites to protect from
further Cas9 recognition and cleavage (binding site mutations, detailed in
Supplementary Table 7). The resulting fragment was inserted using ApaI and
BamHI restriction sites into the pDC2- bsd plasmid43, which expresses the
blasticidin S-deaminase (bsd) selectable marker. Each of the pDC2- pfcpsf3 donor
-bsd-CPSF3donor plasmids encoding PfCPSF3 WT, T406I or Y408S was
transfected eight times into Dd2 parasites by electroporation, along with the
pDC2-cam-Cas9-U6-sgRNA-hdhfr plasmid. Of those eight transfections per
plasmid, two were maintained in 2.5 nM WR99210 and 2 mgml 1 blasticidin,
another two were exposed to 2.5 nM WR99210 and 2 mgml 1 blasticidin for
6 days and then maintained in drug-free media, and four were maintained in
170 nM AN3661. In total, five lines incorporated the PfCPSF3 mutations, along
with silent binding site mutations. Of these 5 lines, one was the result of selection
for the plasmids using 2.5 nM WR99210 and 2 mgml 1 blasticidin, and the other
four were selected with 170 nM AN3661, as detailed in Supplementary Table 7.
Homology modelling of PfCPSF3 and docking analysis of AN3661. Sequences
were from NCBI for human CPSF-73 (gi:18044212), PlasmoDB for PfCPSF3
(PF3D71438400) and PDB for T. thermophiles TTHA0252 HB8 (PDB code: 3IEM).
Sequences were aligned using the NCBI BLAST Clustal Omega method and
Maestro Prime (Schrodinger, LLC). Similarity and identify scores were calculated
using Maestro, not including alignment gaps due to PfCPSF3 insertions. Crystal
structures of human CPSF-73 (PDB code: 2I7T) and T. thermophiles HB8
(PDB code: 3IEM) served as templates to build homology models of PfCPSF3 using
Maestro. The tetrahedral form of AN3661 was generated using Optimized
Potentials for Liquid Simulations 2005 forcefield44 and manually docked into the
active site of the TTHA0252-derived homology model of PfCPSF3, mimicking the
binding mode of benzoxaborole analogues observed from the crystal structures of
MBL NDM-1 (YR Freund, personal communication). The final docking model was
obtained by minimizing the complex using a water solvation model and
maintaining a fixed protein backbone.
RNA stability assay. Ring stage P. falciparumW2 (10–12 h post-invasion) or Dd2
(16–18 h post-invasion) parasites were cultured at 10–15% parasitemia and 2%
haematocrit in a volume of 20ml. Cultures were exposed to 400 nM AN3661,
600 nM chloroquine, 70 nM artemisinin or actinomycin D at either 80 mgml 1 for
W2 or 320 mgml 1 for Dd2. Control cultures were exposed to DMSO at o0.01%
final concentration. After 4 h of drug treatment, parasites were frozen in liquid
nitrogen and stored at  80 C. Total RNA was subsequently extracted using the
Trizol Plus RNA purification kit (Purelink RNA mini kit, Ambion) according to
the manufacturer’s instructions. Briefly, the frozen parasitized RBC pellets were
dissolved in pre-warmed Trizol reagent, followed by chloroform extraction. The
aqueous phase was mixed with ethanol to obtain a final ethanol concentration
of 35% and total RNA was bound, washed, and eluted from the provided spin
cartridges according to the manufacturer’s instructions. For Northern blots, 20 mg
of total RNA was separated on 1.3% formaldehyde agarose gel and transferred to a
Hybond Nþ membrane (Amersham) overnight through capillary action. For
hybridization, RNA was detected using DNA probes labelled with biotin-16-dUTP
(Roche Diagnostics) (Supplementary Table 8). Northern blot signal was detected
using Typhoon Trio imager (Amersham biosciences) and quantified using
ImageQuant software.
Data availability. All relevant data are available from the corresponding author
upon request.
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